SavedAdd your journal

Journals / Haydarpaşa Numune Medical Journal / 2021 / Cilt: 61 - Sayı: 1

The Efficacy of Lacosamide in Children with Drug-resistant Focal Epilepsy

Yeşim COŞKUN
Canan YILDIRIM
Pages
52–57
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is well tolerated and a promising option in these patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: This study aimed to assess the efficacy, tolerability and adverse effects of Lacosamide (LCM) in children with refractory focal epilepsy.
📊
Key Findings & Data:Methods: Children aged younger than 16 years with drug-resistant focal epilepsy were enrolled.
💡
Conclusion & Impact:It is well tolerated and a promising option in these patients.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: This study aimed to assess the efficacy, tolerability and adverse effects of Lacosamide (LCM) in children with refractory focal epilepsy. Methods: Children aged younger than 16 years with drug-resistant focal epilepsy were enrolled. The medical records and seizure diaries that were evaluated every three months were reviewed. Response to LCM was defined as ≥50% reduction in seizure frequency. Results: Twenty-five children with drug-resistant focal epilepsy received LCM as add-on therapy. The mean duration of epi- lepsy was 5.2 years and the mean age at LCM initiation was 8 years. The rate of response to LCM treatment in the 3th, 6th and 9th months were 44%, 64%, 76%, respectively. At the end of 12 months, the response rate was 84% and 16% of the patients were seizure free. Four patients had adverse effects; three patients were discontinued LCM and one improved after decreas- ing the dose of the drug. Discussion and Conclusion: LCM is an effective add-on antiepileptic drug for children with refractory focal epilepsy. It dimin- ishes the frequency of seizures over time. It is well tolerated and a promising option in these patients.

🔖

Cite This Article

COŞKUN, Y., YILDIRIM, C. (2022). The Efficacy of Lacosamide in Children with Drug-resistant Focal Epilepsy. Haydarpaşa Numune Medical Journal, Cilt: 61 - Sayı: 1, 52–57. https://ajindex.com/articles/535879

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Kim JS, Kim H, Lim BC, Chae JH, Choi J, Kim KJ, et al. Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy. Brain Dev 2014;36:510–5
  2. Geerts A, Arts WF, Stroink H, Peeters E, Brouwer O, Peters B, et al. Course and outcome of childhood epilepsy: A 15-year fol- low-up of the dutch study of epilepsy in childhood. Epilepsia 2010;51:1189–97
  3. Berg AT, Rychlik K. The course of childhood-onset epilepsy over the first two decades: A prospective, longitudinal study. Epilepsia 2015;56:40–8
  4. Doty P, Hebert D, Mathy FX, Byrnes W, Zackheim J, Simontac- chi K. Development of lacosamide for the treatment of partial- onset seizures. Ann N Y Acad Sci 2013;1291:56–68
  5. Niespodziany I, Leclère N, Vandenplas C, Foerch P, Wolff C. Comparative study of lacosamide and classical sodium chan- nel blocking antiepileptic drugs on sodium channel slow in- activation. J Neurosci Res 2013;91:436–43
  6. Verrotti A, Loiacono G, Olivieri C, Zulli E, Zaccara G. La- cosamide in patients with pharmacoresistant epilepsy. Expert Opin Pharmacother 2012;13:2065–72
  7. Rosati A, Ilvento L, Rizzi R, Doccini V, Leo MC, Pugi A, et al. Long-term efficacy of add-on lacosamide treatment in chil- dren and adolescents with refractory epilepsies: A single-cen- ter observational study. Epilepsia 2018;59:1004–10
  8. Hoy SM. Lacosamide: A review of its use as adjunctive ther- apy in the management of partial-onset seizures. CNS Drugs 2013;27:1125–42
  9. Rüegger AD, Freeman JL, Harvey AS. Lacosamide in chil- dren with drug-resistant epilepsy. J Paediatr Child Health 2019;55:194–8
  10. Miskin C, Khurana DS, Valencia I, Legido A, Hasbani DM, Car- valho KS, et al. Efficacy and tolerability of lacosamide in the treatment of children with refractory generalized epilepsy. J Child Neurol 2016;31:925–8
  11. Guilhoto LM, Loddenkemper T, Gooty VD, Rotenberg A, Take-oka M, Duffy FH, et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol 2011;44:414–9
  12. Arkilo D, Gustafson M, Ritter FJ. Clinical experience of intrave- nous lacosamide in infants and young children. Eur J Paediatr Neurol 2016;20:212–7
  13. Pasha I, Kamate M, Didagi SK. Efficacy and tolerability of la- cosamide as an adjunctive therapy in children with refractory partial epilepsy. Pediatr Neurol 2014;51:509–14
  14. Heyman E, Lahat E, Levin N, Berkovitch M, Gandelman-Marton R. Preliminary efficacy and safety of lacosamide in children with refractory epile